In an effort to spur adoption of healthcare technology, namely electronic prescribing and electronic health records, the federal government began instituting financial incentives that encourage use of these products. As a result, usage has surged over the past five years, according to our survey of 70 PCPs, 70 endocrinologists, and 25 MCO pharmacy directors. Physicians are now more acutely aware of MCOs’ formularies and are therefore more likely to prescribe more favorably reimbursed drugs as well as better identify undiagnosed patients, sharply impacting their prescribing decisions for diabetes and hypertension therapies. By understanding the impact of these healthcare technology trends on physician behavior, drug marketers can plan to either withstand the headwinds emerging from this movement or take advantage of dynamics that favor their therapies.
This U.S. Physician and Payer Forum explores how the adoption of e-prescribing and electronic health records is affecting the prescribing of diabetes and hypertension drugs by endocrinologists and PCPs, highlighting the role of market access for drugs treating these indications. This report will survey 70 endocrinologists and 70 PCPs as well as 25 MCO PDs, and will examine the impact on currently marketed brands Merck’s Januvia and Cozaar; AstraZeneca’s Onglyza and Atacand; Boehringer Ingelheim’s Tradjenta and Micardis; Novartis’ Diovan and Tekturna; Daiichi’s Benicar; BMS/Sanofi’s Avapro; Takeda’s Edarbi; and Forest’s Bystolic.
Markets covered: United States.
Primary research: Online survey of 70 endocrinologists, 70 PCPs, and 25 MCO pharmacy directors.
Epidemiology: Type 2 diabetes; Hypertension.
Population segments in market forecast: Patients within Medicare and Medicaid.